Litifilimab

DB18864InvestigationalProtein Based Therapies

Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) And/or Chronic...

Mechanism: Pharmacologically active on C-type lectin domain family 4 member C
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human blood dendritic cell antigen 2) (human-mus musculus monoclonal biib059 .gamma.1-chain), disulfide with human-mus musculus monoclonal biib059 .kappa.-chain, dimer
Code names: 24F4A · BIIB-059

Resolves to

Compound

UNIIV27E9V3K7GCAS2407378-48-5

Targets

Q8WTT0CLEC4C

What you can answer from here — as of March 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Litifilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account